Research guide · Metabolic Support
Ipamorelin — research protocol
Selective growth hormone secretagogue studied for pulsatile GH release without significant cortisol or prolactin elevation.
This guide summarizes study areas and sources associated with the compound. BioPeptideX does not convert experimental information into a clinical regimen or recommend an individual dose, frequency, route or duration.
Catalog presentations
Concentration table
Mathematical reference only; this is not a dosing recommendation.
Research areas
- Selective GHRP compound
- Lyophilized powder for stability
- 99% HPLC verified purity
Most-cited research protocols
Educational information based on research protocols and literature; it does not replace guidance from a healthcare professional.
Ipamorelin is a research peptide that stimulates the body to release its own growth hormone in short, natural pulses. It is preferred in research protocols because it does not significantly raise cortisol, prolactin, or other unwanted hormones.
| Dose | Frequency | Duration | Route | |
|---|---|---|---|---|
| Assessment | 100 mcg/day | 1x at bedtime, fasted | Week 1 | Subcutaneous |
| Titration | 200 mcg/day | 1x bedtime, or split 100 mcg AM + 100 mcg PM | Weeks 2-3 | Subcutaneous |
| Standard | 200-300 mcg/day | 1-2x daily (AM fasted + bedtime is common) | Weeks 4-8 | Subcutaneous |
| Extended | 200-300 mcg/day | Continue if tolerated. Some protocols run to week 16. | Weeks 9-12 | Subcutaneous |
Cycle: 8 to 12 weeks on, then 4 weeks off
Benefits and research observations: GH peaks 30-40 minutes after a single shot. Early side effects like mild headache or tingling may occur in days 1-7, and generally fade by weeks 2-4.
Handling and storage
Store unreconstituted product according to its label and maintain the cold chain where applicable. After any preparation, follow only validated instructions for the specific product and diluent. Do not use if packaging is damaged or the solution shows particles or unexpected changes.
Warnings
Do not use this page for self-diagnosis or self-medication. Pregnancy, breastfeeding, minors, cancer history, allergies, active disease and concurrent treatments require individual professional evaluation.
Published sources
- 1.Raun K, et al. Eur J Endocrinol, 1998.
- 2.Gobburu JV, et al. Pharm Res, 1999.